Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2022-01-26 Major Shareholding Noti…
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-01-26 English
8-K - NIH AND JPM
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a patent license agreement with NIH), a corporate presentation to be given at a healthcare conference, and a press release announcing the agreement. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document primarily announces a material contract and provides an investor presentation as an exhibit. This fits best under the category of Capital/Financing Update (CAP) because it involves a significant licensing agreement impacting the company's intellectual property and potential commercial activities. The presence of a corporate presentation related to the agreement further supports CAP rather than a pure investor presentation (IP) or regulatory filing (RNS). The document length (8473 characters) and detailed description of the agreement confirm it is not a brief announcement or mere report publication notice. Therefore, the most appropriate classification is CAP with high confidence.
2022-01-11 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2021, by Sana Biotechnology, Inc. It announces the issuance of a press release containing financial results for the quarter ended September 30, 2021. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1) that contains the earnings information. The text explicitly states that the information is being furnished and is not "filed" for certain regulatory purposes, indicating this is an announcement rather than the full earnings report. The document length is 3416 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is best classified as an Earnings Release (ER) since it announces quarterly financial results via a press release, which is typical for earnings releases filed as 8-Ks.
2021-11-08 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes Sana Biotechnology entering into a material definitive agreement with Beam Therapeutics, detailing the terms of the license agreement. It also references that the full agreement will be filed as an exhibit to the next Quarterly Report on Form 10-Q. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement of a material event. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 8-K filings reporting material agreements.
2021-10-19 English
PRIMARY DOCUMENT
Director's Dealing
2021-09-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.